Titre : Antigène HLA-B37

Antigène HLA-B37 : Questions médicales fréquentes

Termes MeSH sélectionnés :

Memory B Cells
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Antigène HLA-B37 : Questions médicales les plus fréquentes", "headline": "Antigène HLA-B37 : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Antigène HLA-B37 : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-06-19", "dateModified": "2025-03-16", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Antigène HLA-B37" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Antigènes HLA-B", "url": "https://questionsmedicales.fr/mesh/D015235", "about": { "@type": "MedicalCondition", "name": "Antigènes HLA-B", "code": { "@type": "MedicalCode", "code": "D015235", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D23.050.705.552.450.380" } } }, "about": { "@type": "MedicalCondition", "name": "Antigène HLA-B37", "alternateName": "HLA-B37 Antigen", "code": { "@type": "MedicalCode", "code": "D059912", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Apostolos P Georgopoulos", "url": "https://questionsmedicales.fr/author/Apostolos%20P%20Georgopoulos", "affiliation": { "@type": "Organization", "name": "The HLA Research Group, Brain Sciences Center, Department of Veterans Affairs Health Care System, Minneapolis, MN, USA." } }, { "@type": "Person", "name": "Lisa M James", "url": "https://questionsmedicales.fr/author/Lisa%20M%20James", "affiliation": { "@type": "Organization", "name": "The HLA Research Group, Brain Sciences Center, Department of Veterans Affairs Health Care System, Minneapolis, MN, USA." } }, { "@type": "Person", "name": "Arie Admon", "url": "https://questionsmedicales.fr/author/Arie%20Admon", "affiliation": { "@type": "Organization", "name": "Faculty of Biology, Technion Israel Institute of Technology, Haifa, Israel admon@technion.ac.il Michael.peled@sheba.health.gov.il." } }, { "@type": "Person", "name": "Spyros A Charonis", "url": "https://questionsmedicales.fr/author/Spyros%20A%20Charonis", "affiliation": { "@type": "Organization", "name": "The HLA Research Group, Brain Sciences Center, Department of Veterans Affairs Health Care System, Minneapolis, MN, USA." } }, { "@type": "Person", "name": "Matthew Sanders", "url": "https://questionsmedicales.fr/author/Matthew%20Sanders", "affiliation": { "@type": "Organization", "name": "The HLA Research Group, Brain Sciences Center, Department of Veterans Affairs Health Care System, Minneapolis, MN, USA." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "Identification of memory B-cell-associated miRNA signature to establish a prognostic model in gastric adenocarcinoma.", "datePublished": "2023-09-21", "url": "https://questionsmedicales.fr/article/37735667", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1186/s12967-023-04366-2" } }, { "@type": "ScholarlyArticle", "name": "Single-cell profiling reveals a memory B cell-like subtype of follicular lymphoma with increased transformation risk.", "datePublished": "2022-11-09", "url": "https://questionsmedicales.fr/article/36351924", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1038/s41467-022-34408-0" } }, { "@type": "ScholarlyArticle", "name": "JAK inhibitors attenuate hyperactivation of nonswitched memory B cells in rheumatoid arthritis patients in remission.", "datePublished": "2024-07-17", "url": "https://questionsmedicales.fr/article/39020445", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1186/s13075-024-03374-x" } }, { "@type": "ScholarlyArticle", "name": "Modeling memory B cell responses in a lymphoid organ-chip to evaluate mRNA vaccine boosting.", "datePublished": "2024-09-06", "url": "https://questionsmedicales.fr/article/39240335", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1084/jem.20240289" } }, { "@type": "ScholarlyArticle", "name": "Dynamics of SARS-CoV-2-Specific B Cell Memory Responses in Infected and Vaccinated Individuals.", "datePublished": "2023-05-04", "url": "https://questionsmedicales.fr/article/37140898", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1089/vim.2022.0197" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Facteurs biologiques", "item": "https://questionsmedicales.fr/mesh/D001685" }, { "@type": "ListItem", "position": 3, "name": "Antigènes", "item": "https://questionsmedicales.fr/mesh/D000941" }, { "@type": "ListItem", "position": 4, "name": "Isoantigènes", "item": "https://questionsmedicales.fr/mesh/D007519" }, { "@type": "ListItem", "position": 5, "name": "Antigènes d'histocompatibilité", "item": "https://questionsmedicales.fr/mesh/D006649" }, { "@type": "ListItem", "position": 6, "name": "Antigènes HLA", "item": "https://questionsmedicales.fr/mesh/D006680" }, { "@type": "ListItem", "position": 7, "name": "Antigènes HLA-B", "item": "https://questionsmedicales.fr/mesh/D015235" }, { "@type": "ListItem", "position": 8, "name": "Antigène HLA-B37", "item": "https://questionsmedicales.fr/mesh/D059912" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Antigène HLA-B37 - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Antigène HLA-B37", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-05", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Antigène HLA-B37", "description": "Comment détecte-t-on l'antigène HLA-B37 ?\nQuels tests sont utilisés pour le HLA-B37 ?\nLe HLA-B37 est-il associé à des maladies spécifiques ?\nQui doit se faire tester pour HLA-B37 ?\nQuelle est l'importance du HLA-B37 dans le diagnostic ?", "url": "https://questionsmedicales.fr/mesh/D059912?mesh_terms=Memory+B+Cells&page=3#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Antigène HLA-B37", "description": "Quels symptômes sont liés à HLA-B37 ?\nHLA-B37 cause-t-il des symptômes directs ?\nPeut-on avoir des symptômes sans HLA-B37 ?\nLes symptômes varient selon les individus ?\nHLA-B37 est-il lié à des symptômes allergiques ?", "url": "https://questionsmedicales.fr/mesh/D059912?mesh_terms=Memory+B+Cells&page=3#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Antigène HLA-B37", "description": "Peut-on prévenir les maladies liées à HLA-B37 ?\nY a-t-il des mesures préventives spécifiques ?\nLes tests génétiques aident-ils à la prévention ?\nLes vaccinations sont-elles utiles ?\nLe stress influence-t-il les maladies liées à HLA-B37 ?", "url": "https://questionsmedicales.fr/mesh/D059912?mesh_terms=Memory+B+Cells&page=3#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Antigène HLA-B37", "description": "Quels traitements sont disponibles pour les maladies liées à HLA-B37 ?\nLe traitement dépend-il du type de maladie ?\nLes greffes sont-elles affectées par HLA-B37 ?\nY a-t-il des traitements préventifs pour HLA-B37 ?\nLes traitements sont-ils efficaces ?", "url": "https://questionsmedicales.fr/mesh/D059912?mesh_terms=Memory+B+Cells&page=3#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Antigène HLA-B37", "description": "Quelles complications peuvent survenir avec HLA-B37 ?\nHLA-B37 augmente-t-il le risque de cancer ?\nLes complications sont-elles réversibles ?\nComment prévenir les complications liées à HLA-B37 ?\nLes complications varient-elles selon les individus ?", "url": "https://questionsmedicales.fr/mesh/D059912?mesh_terms=Memory+B+Cells&page=3#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Antigène HLA-B37", "description": "Quels sont les facteurs de risque pour HLA-B37 ?\nL'âge influence-t-il le risque lié à HLA-B37 ?\nLe sexe joue-t-il un rôle dans le risque ?\nLes infections augmentent-elles le risque ?\nLe mode de vie influence-t-il le risque ?", "url": "https://questionsmedicales.fr/mesh/D059912?mesh_terms=Memory+B+Cells&page=3#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment détecte-t-on l'antigène HLA-B37 ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "Par des tests de typage HLA, souvent réalisés sur des échantillons de sang." } }, { "@type": "Question", "name": "Quels tests sont utilisés pour le HLA-B37 ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Les tests de compatibilité tissulaire et les analyses de sang sont courants." } }, { "@type": "Question", "name": "Le HLA-B37 est-il associé à des maladies spécifiques ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Oui, il est lié à certaines maladies auto-immunes et à des réactions de greffe." } }, { "@type": "Question", "name": "Qui doit se faire tester pour HLA-B37 ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Les personnes ayant des antécédents familiaux de maladies auto-immunes ou nécessitant une greffe." } }, { "@type": "Question", "name": "Quelle est l'importance du HLA-B37 dans le diagnostic ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "Il aide à évaluer la compatibilité pour les greffes et à identifier des risques de maladies." } }, { "@type": "Question", "name": "Quels symptômes sont liés à HLA-B37 ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Les symptômes varient selon les maladies associées, comme la fatigue ou des douleurs articulaires." } }, { "@type": "Question", "name": "HLA-B37 cause-t-il des symptômes directs ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Non, il n'y a pas de symptômes directs, mais il est associé à des maladies symptomatiques." } }, { "@type": "Question", "name": "Peut-on avoir des symptômes sans HLA-B37 ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Oui, de nombreuses maladies auto-immunes peuvent survenir sans HLA-B37." } }, { "@type": "Question", "name": "Les symptômes varient selon les individus ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Oui, la réponse immunitaire et les symptômes peuvent varier d'une personne à l'autre." } }, { "@type": "Question", "name": "HLA-B37 est-il lié à des symptômes allergiques ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Non, HLA-B37 est principalement associé à des maladies auto-immunes, pas aux allergies." } }, { "@type": "Question", "name": "Peut-on prévenir les maladies liées à HLA-B37 ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "La prévention est difficile, mais un suivi médical régulier peut aider à détecter précocement." } }, { "@type": "Question", "name": "Y a-t-il des mesures préventives spécifiques ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Adopter un mode de vie sain et éviter les facteurs de risque peut être bénéfique." } }, { "@type": "Question", "name": "Les tests génétiques aident-ils à la prévention ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les tests peuvent identifier les personnes à risque et permettre une surveillance." } }, { "@type": "Question", "name": "Les vaccinations sont-elles utiles ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Les vaccinations peuvent aider à prévenir certaines infections, mais pas directement liées à HLA-B37." } }, { "@type": "Question", "name": "Le stress influence-t-il les maladies liées à HLA-B37 ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Le stress peut aggraver les symptômes des maladies auto-immunes, donc sa gestion est importante." } }, { "@type": "Question", "name": "Quels traitements sont disponibles pour les maladies liées à HLA-B37 ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Les traitements incluent des immunosuppresseurs et des thérapies ciblées selon la maladie." } }, { "@type": "Question", "name": "Le traitement dépend-il du type de maladie ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le traitement est adapté en fonction de la maladie auto-immune spécifique." } }, { "@type": "Question", "name": "Les greffes sont-elles affectées par HLA-B37 ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "Oui, HLA-B37 influence la compatibilité et le risque de rejet lors des greffes." } }, { "@type": "Question", "name": "Y a-t-il des traitements préventifs pour HLA-B37 ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "Il n'existe pas de traitement préventif spécifique, mais un suivi médical est conseillé." } }, { "@type": "Question", "name": "Les traitements sont-ils efficaces ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "L'efficacité varie selon la maladie et la réponse individuelle au traitement." } }, { "@type": "Question", "name": "Quelles complications peuvent survenir avec HLA-B37 ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Des complications incluent le rejet de greffe et des exacerbations de maladies auto-immunes." } }, { "@type": "Question", "name": "HLA-B37 augmente-t-il le risque de cancer ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Certaines études suggèrent un risque accru de cancers associés aux maladies auto-immunes." } }, { "@type": "Question", "name": "Les complications sont-elles réversibles ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "Certaines complications peuvent être gérées, mais d'autres peuvent être permanentes." } }, { "@type": "Question", "name": "Comment prévenir les complications liées à HLA-B37 ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Un suivi médical régulier et un traitement approprié peuvent aider à prévenir les complications." } }, { "@type": "Question", "name": "Les complications varient-elles selon les individus ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les complications peuvent varier en fonction de la génétique et de l'état de santé général." } }, { "@type": "Question", "name": "Quels sont les facteurs de risque pour HLA-B37 ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "Les antécédents familiaux de maladies auto-immunes et certains facteurs environnementaux." } }, { "@type": "Question", "name": "L'âge influence-t-il le risque lié à HLA-B37 ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Oui, certaines maladies auto-immunes liées à HLA-B37 apparaissent plus fréquemment chez les jeunes adultes." } }, { "@type": "Question", "name": "Le sexe joue-t-il un rôle dans le risque ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Oui, certaines maladies auto-immunes sont plus fréquentes chez les femmes que chez les hommes." } }, { "@type": "Question", "name": "Les infections augmentent-elles le risque ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Certaines infections peuvent déclencher des maladies auto-immunes chez les individus prédisposés." } }, { "@type": "Question", "name": "Le mode de vie influence-t-il le risque ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Oui, un mode de vie malsain peut augmenter le risque de développer des maladies auto-immunes." } } ] } ] }

Sources (10000 au total)

Identification of memory B-cell-associated miRNA signature to establish a prognostic model in gastric adenocarcinoma.

Memory B cells and microRNAs (miRNAs) play important roles in the progression of gastric adenocarcinoma (GAC), also known as stomach adenocarcinoma (STAD). However, few studies have investigated the u... We identified the marker genes of memory B cells by single-cell RNA sequencing (scRNA-seq) and identified the miRNAs associated with memory B cells by constructing an mRNA‒miRNA coexpression network. ... Four memory B-cell-associated miRNAs (hsa-mir-145, hsa-mir-125b-2, hsa-mir-100, hsa-mir-221) with significant correlations to OS were identified and used to construct a prognostic model. Time-dependen... In summary, we identified memory B-cell-associated miRNA prognostic features and constructed a novel risk model for STAD based on scRNA-seq data and bulk RNA-seq data. Among patients in the high-risk ...

JAK inhibitors attenuate hyperactivation of nonswitched memory B cells in rheumatoid arthritis patients in remission.

To investigate the distribution and activation of B-cell subpopulations in rheumatoid arthritis (RA) patients treated with Janus kinase inhibitors (JAKis) and to analyze their correlation with disease... Peripheral blood samples were collected from 23 adult healthy controls and 58 RA patients, 31 of whom were treated with JAKis and assessed during a 24-month follow-up. The number of peripheral B-cell ... Compared with that in healthy controls, the frequency of NSMB cells was significantly lower in new-onset untreated RA patients. However, expression of CD40, CD80, CD95, CD21... RA patients present different B-cell subpopulations, in which the frequency of NSMB cells is negatively associated with disease activity. However, treatment with JAKis can inhibit activation of NSMB c...

Human regulatory memory B cells defined by expression of TIM-1 and TIGIT are dysfunctional in multiple sclerosis.

Regulatory B cells (Bregs) play a pivotal role in suppressing immune responses, yet there is still a lack of cell surface markers that can rigorously identify them. In mouse models for multiple sclero... FACS-sorted TIM-1+/-TIGIT+/- memory B (memB) cells co-cultured with allogenic CD4+ T cells were analyzed for proliferation and induction of inflammatory markers using flow cytometry and cytokine quant... TIM-1-TIGIT- double negative (DN) memB cells strongly induce T cell proliferation and pro-inflammatory cytokine expression. The TIM-1+ memB cells enabled low levels of CD4+ T cell activation and gave ... These findings demonstrate that TIM-1/TIGIT expressing memory B cell subsets have distinct functionalities. Co-expression of TIM-1 and TIGIT defines a regulatory memory B cell subset that is functiona...

Coordinated expansion of memory T follicular helper and B cells mediates spontaneous clearance of HCV reinfection.

Follicular helper T cells are essential for helping in the maturation of B cells and the production of neutralizing antibodies (NAbs) during primary viral infections. However, their role during recall... We evaluated this interaction longitudinally in subjects who have spontaneously resolved primary HCV infection during a subsequent reinfection episode that resulted in either another spontaneous resol... Both groups exhibited virus-specific memory T cells that expanded upon reinfection. However, early expansion of activated cTfh (CD4... These results underscore a key role for early activation of cTfh1 cells in helping antigen-specific B cells to produce NAbs that mediate the clearance of HCV reinfection....

Memory B Cell Activation Induced by Pertussis Booster Vaccination in Four Age Groups of Three Countries.

Immunogenicity of acellular pertussis (aP) vaccines is conventionally assessed by measuring antibody responses but antibody concentrations wane quickly after vaccination. Memory B cells, however, are ... We studied pertussis specific memory B cell (re)activation induced by an aP booster vaccination in four different age groups within three countries.... From a phase IV longitudinal interventional study, 268 participants across Finland, the Netherlands and the United Kingdom were included and received a 3-component pertussis booster vaccine: children ... Geometric mean (GM) memory B cell frequencies for pertussis antigens at baseline were low. At 28 days post-vaccination, these frequencies increased within each age group and were still elevated one ye... An aP booster vaccine (re)activated memory B cells in all age groups. Still elevated memory B cell frequencies after one year indicates enhanced immunological memory. However, antigen specific memory ...